Oneoncology Research Network LLC

1. Genentech, Inc. $999,776 296 payments
2. GlaxoSmithKline, LLC. $364,585 92 payments
3. Mirati Therapeutics, Inc. $288,915 70 payments
4. Regeneron Pharmaceuticals, Inc. $273,596 49 payments

1. Mytactic Targeting Actionable Mutation Study in Cancer US Piia Multicenter Nonrandomized Open LBL $887,822 258 payments
2. A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation $288,915 70 payments
3. A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma $251,096 45 payments
4. A Phase 2 Open-Label Study to Evaluate Momelotinib in Combination With $123,892 20 payments
5. Tiragolumab Tecentriq VS Durvalumab in Unresectable Stage III Nsclc $100,441 37 payments
6. A Randomized, Multicenter, Double-Blind, Phase 3 Study to Investigate $81,368 22 payments
7. A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab M $73,800 23 payments
8. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evalua $51,906 20 payments
9. A Phase 2, Randomized, Open-Label, Platform Study Utilizing A Master P $33,619 7 payments
10. A Randomized Phase 2 Platform Study to Evaluate Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for the Perioperative Treatment of Patients With Resectable Non-Small Cell Lung Cancer $22,500 4 payments

1. Non-patient care $271,790 65 payments
2. Patient care $17,125 5 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.